Dawn Sperling, NP
Nurse Practitioner · Marion, OHNPI 1851543185
Payments from drug & device makers
Across 102 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$344
- Beigene USA, Inc.$125
- GSK$125
- Lilly USA, LLC$123
- Novo Nordisk$119
- AstraZeneca$106
- plus $801 from 21 others
What the payments were for
- Food & beverage$1,742100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $344 |
| Beigene USA, Inc. | 1 | $125 |
| GSK | 9 | $125 |
| Lilly USA, LLC | 8 | $123 |
| Novo Nordisk | 8 | $119 |
| AstraZeneca | 8 | $106 |
| Astellas Pharma US Inc | 6 | $97 |
| Bayer | 6 | $96 |
| Amgen | 4 | $54 |
| Abbott | 3 | $54 |
| Pfizer | 3 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Mylan Specialty L.p. | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Novartis | 3 | $41 |
| Sanofi | 1 | $40 |
| Johnson & Johnson | 2 | $35 |
| Exact Sciences | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Viiv Healthcare Company | 1 | $15 |
| Dynavax Technologies Corporation | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRUKINSA$125
How this compares
$1,742 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $76,726 |
| OzempicSemaglutide | 53 | $63,868 |
| JardianceEmpagliflozin | 40 | $51,358 |
| TrulicityDulaglutide | 38 | $41,221 |
| XifaxanRifaximin | 13 | $37,572 |
| Repatha SureclickEvolocumab | 17 | $13,994 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $12,929 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $11,938 |
| JanuviaSitagliptin Phosphate | 13 | $11,593 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $11,184 |
| EntrestoSacubitril/Valsartan | 11 | $7,448 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,263 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $5,348 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 137 | $4,163 |
| DuleraMometasone/Formoterol | 12 | $4,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $54 | $76,72667 claims |
| Novo NordiskOzempic | $119 | $63,86853 claims |
| Boehringer IngelheimJardiance | $16 | $51,35840 claims |
| Lilly USA, LLCTrulicity | $123 | $41,22138 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $47 | $37,57213 claims |
| GSKBreo Ellipta, Anoro Ellipta | $125 | $18,20134 claims |
| MerckJanuvia, Dulera | $12 | $15,71125 claims |
| NovartisEntresto | $41 | $7,44811 claims |
| AbbVieSynthroid | $344 | $1,10922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Marion
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.